Shire Asks Fed. Circ. To Undo Generic's Win In Lialda Suit

Law360, Washington (May 1, 2017, 2:54 PM EDT) -- Shire PLC on Monday fought to overturn a decision giving Zydus Pharmaceuticals Inc. the green light to bring its generic version of Shire's gastrointestinal drug Lialda to market, telling a Federal Circuit panel the trial court unfairly limited the scope of its patent covering the drug.

Shire has appealed a Delaware federal court's ruling that the generic version of Lialda proposed by Cadila Healthcare Ltd. and Zydus, Cadila's U.S. unit, in their abbreviated new drug application would not infringe claims 1 and 3 of Shire's U.S. Patent Number 6,773,720, which does not expire until 2020.

Shire has argued that U.S. District...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!